Here’s What the Street is Saying About Amgen Inc. (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. (NASDAQ:AMGN) was downgraded to Hold from Buy by Freedom Capital, with the firm adjusting the price target on the stock to $375 from $360. It told investors in a research note that while it views the company’s fiscal Q4 report as “strong”, the shares are at fair value and loss of exclusivity headwinds remain for Amgen Inc. (NASDAQ:AMGN). RBC Lifts Amgen (AMGN) Target After Strong Q4 ...